84 results about "Traitement adjuvant" patented technology

The invention discloses a system and a method for predicting postoperative recurrence risk after triple negative breast cancer neoadjuvant therapy based on multi-modal time sequence medical image data, and belongs to the field of medical image analysis. The system comprises a data processing module used for constructing a multi-modal data set; the multi-modal feature extraction and screening module is used for extracting deep learning, radiomics and tumor habitat features from the region and carrying out feature screening; the model training module is used for constructing a time sequence model based on a Transform architecture and carrying out training through a multi-task learning strategy integrated with time consistency constraint and gene association auxiliary loss; and the recurrence risk prediction module is used for loading the trained model and outputting a recurrence probability and a risk level. According to the method, the multi-modal time sequence image and gene information are fused, so that the recurrence risk of the triple negative breast cancer patient is dynamically and accurately quantified, and support is provided for clinical individualized treatment decision.

The discovery and application of immune checkpoint inhibitors (ICI) have significantly promoted cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. To explore novel adjuvant treatment options, we performed fecal microbiota transplantation (FMT) of healthy donors on 10 GI cancer patients with resistance to anti-PD-(L) 1 treatment. The combination of FMT and anti-PD1 treatment was well tolerated and no serious adverse reaction was observed. Two out of 10 patients restored clinical responsiveness to anti-PD1 after FMT. Clinical benefits were shown to be associated with better colonization of co-occurred immunogenic microbes from donors, alongside activated immune status reflected by the peripheral immune cell population. Moreover, we identified microbial signatures of ICI responsiveness and validated in an independent cohort. Our study demonstrates the feasibility of FMT as a potential adjuvant therapy for ICI irresponsive GI cancer patients and laid a foundation for LBP / consortia development to enhance ICI efficacy.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The invention discloses application of SNRPD3 in preparation of a medicine for treating ovarian cancer, and belongs to the technical field of biological medicine. The invention provides application of a reagent for inhibiting or down-regulating SNRPD3 expression in preparation of drugs for treatment or adjuvant treatment of ovarian cancer. The reagent is siRNA or an ASO drug targeting SNRPD3. The invention proves that the apoptosis of the serous ovarian cancer cells can be increased and the growth of transplanted tumors of the serous ovarian cancer cells in mice can be inhibited by interfering the expression of the SNRPD3; an ASO drug targeting SNRPD3 can reduce SNRPD3 expression, and in-vitro experiments prove that the ASO drug can inhibit malignant biological behaviors of ovarian cancer cells; the siRNA is combined to inhibit SNRPD3 and a PARP inhibitor (PARPi) to treat ovarian cancer cells, and in-vitro experiments prove that the apoptosis ratio of the ovarian cancer cells is obviously increased by combining the siRNA and the PARP inhibitor. The invention provides a new treatment approach for ovarian cancer treatment.

According to the breast cancer prediction model construction system based on the MRI image and the storage medium provided by the invention, the model for predicting the neoadjuvant chemotherapy pathological alleviation condition and prognosis of the breast cancer patient is constructed by combining the dynamic change of the blood vessel characteristics and the clinical pathological characteristics, so that the system has relatively high accuracy and clinical practicability, and is suitable for popularization and application. And making of an individualized adjuvant therapy scheme is facilitated. The method can early predict breast pathology remission and long-term prognosis, and can early and accurately predict neoadjuvant chemotherapy curative effect and long-term prognosis of breast cancer patients. The model predicts whether a patient can achieve complete relieving of breast pathology or not by analyzing changes of breast tumor blood vessel characteristics in the chemotherapy process and correlation with clinical factors, and further predicts the recurrence-free lifetime of the patient, so that a reference basis is provided for individualized treatment.

The invention provides a breast cancer adjuvant therapy pathology complete remission prediction method and electronic device.The breast cancer adjuvant therapy pathology complete remission prediction method comprises the steps that at the first stage, based on multi-time-point and multi-parameter MRI images of a patient before and after adjuvant therapy, the breast cancer adjuvant therapy pathology complete remission prediction result is obtained; training an image feature encoder with a tumor dynamic change identification capability through a dynamic supervision pre-training mode; and a second stage of constructing a multi-modal deep fusion network based on the image feature encoder to integrate the image features, radiomics features and clinical pathological features of the patient, and outputting a prediction result of complete pathology remission, the radiomics features being extracted from the MRI image. And the purposes of high precision and strong generalization capability are achieved.

The invention discloses an application of wheat flavone in preparation of a medicine for an SRC / MAPK / AP-1 / PD-L1 signal channel inhibitor and an application of the combined action of the wheat flavone and the PD-1 / PD-L1 inhibitor in preparation of a medicine for treating KRAS mutant non-small cell lung cancer. The wheat flavone can make up the deficiency of immunotherapy and enhance the anti-tumor activity of a PD-1 / PD-L1 inhibitor, and has great potential for adjuvant therapy of KRAS mutant non-small cell lung cancer.

The present invention provides novel conjugates comprising a magnetic particle and a multitude of viral structures covalently bound to said particle. These conjugates are suited for efficient extracorporeal removal of antibodies from blood. In particular, the conjugates are suited as adjuvant treatment in gene therapy.

The invention relates to the technical field of biological medicine, and relates to a polypeptide in targeted combination with SOX2 protein and application thereof, the polypeptide has an amino acid sequence as shown in SEQ ID NO.1, or has at least 85%, 90%, 95% or more than 99% of sequence identity with the amino acid sequence; the polypeptide inhibits phase separation of SOX2, liquid drops formed by phase separation of SOX2 can be avoided, then the situation that the liquid drops wrap chemotherapeutic drugs, influence the curative effect of the chemotherapeutic drugs and cause tolerance of tumor cells to the chemotherapeutic drugs is avoided, and the polypeptide does not influence the transcription activation function of SOX2 serving as a transcription factor; the polypeptide can inhibit the phase separation of the SOX2, so that the regulation of normal physiological functions, such as high expression in organs such as eyes of a human body, of the SOX2 as a transcription factor is not influenced, and therefore, the polypeptide disclosed by the invention can reverse chemotherapy drug resistance of tumors such as squamous carcinoma by inhibiting the phase separation of the SOX2, can be used for adjuvant therapy of the tumors such as squamous carcinoma, and has no obvious toxic or side effect on each organ of an organism.

The invention discloses application of a small molecule compound in preparation of a medicine for treating ovarian cancer, and belongs to the technical field of biological medicine. The small molecule compound comprises a structure as shown in a formula (I) or an isomer, a pharmaceutically acceptable solvate or salt thereof, it is found for the first time that the small molecule compound can effectively reduce protein expression of YBX1, and meanwhile in-vitro verification experiments prove that the small molecule compound has a remarkable inhibition effect on proliferation of ovarian cancer cells. In addition, it is found that the small molecule compound can improve the cytotoxicity of cis-platinum and significantly enhance the anti-tumor effect of cis-platinum. The application of the small molecule compound YB-B1 targeting YBX1 in preparation of the medicine for treating the ovarian cancer is disclosed for the first time, a new method and a new idea are provided for clinical treatment of the ovarian cancer, and the small molecule compound YB-B1 particularly has remarkable significance in auxiliary treatment and prevention and treatment of cis-platinum drug-resistant ovarian cancer.

The present invention discloses an adjuvant treatment of node-positive, carly stage, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2—) breast cancer comprising administering an effective amount of an endocrine therapy in combination with an effective amount of abemaciclib or a pharmaceutically acceptable salt thereof.

Indivi dualized neoantigen vaccines, as well as methods for their use in subjects to treat urothelial orbladder cancer are provided. In some embodiments, individualized neoantigen vaccines are used with an immune checkpoint inhibitor and optionally enfortumab vedotin to treat a urothelial or bladder cancer after surgical resection. Prior to surgical resection, in some embodiments, the subject is administered a neoadjuvant therapy comprising an immune checkpoint inhibitor, individualized neoantigen vaccines, and, optionally, enfortumab vedotin.

The invention discloses a targeting peptide for blocking combination of IL-17A and IL-17RA / RC and application thereof, the targeting peptide is selected from AZS-1, AZS-2, AZS-3, AZS-4 and AZS-5 or a combination of any one of AZS-1, AZS-2, AZS-3, AZS-4 and AZS-5 and IBP, the amino acid sequence of AZS-1 is as shown in SEQ ID NO: 1, the amino acid sequence of AZS-2 is as shown in SEQ ID NO: 2, the amino acid sequence of AZS-3 is as shown in SEQ ID NO: 3, the amino acid sequence of AZS-4 is as shown in SEQ ID NO: 4, and the amino acid sequence of AZS-5 is as shown in SEQ ID NO: 5. The amino acid sequence of the AZS-5 is as shown in SEQ ID NO: 5, and the amino acid sequence of the IBP is as shown in SEQ ID NO: 6. The targeting peptide provided by the invention has good tolerance, can generate effective interaction with the surface of a target protein, can realize specific binding with IL-17A, has relatively high blocking ability, can effectively improve symptoms of liver and kidney cell injury, cell edema and skin injury caused by psoriasis after being applied to a psoriasis mouse model, and has a good application prospect. The compound has a good application prospect in treatment and / or adjuvant therapy of IL-17A-mediated inflammatory diseases.

The invention discloses application of HSF1A in preparation of a medicine for resisting lung cancer metastasis, and relates to the technical field of anti-tumor medicines. It is found for the first time that HSF1A can be used for inhibiting non-small cell lung cancer metastasis. The HSF1A is specifically combined with a CCT1 subunit ATPase structural domain of a TRIC / CCT compound, so that the protein folding function of the TRIC / CCT compound is interfered, and three key transfer promoting signal channels including YAP, STAT3 and mTOR are inhibited at the same time. In a pulmonary metastatic tumor model constructed by mouse tail intravenous injection, the formation of pulmonary metastatic tumor is obviously reduced by the HSF1A, and the fact that the HSF1A also has strong anti-metastatic capability in an in-vivo environment is proved; the safety is high, and the development and utilization prospects are good. The invention not only provides a new application of the HSF1A, but also provides a new thought and method for adjuvant therapy of cancers.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of LAP3 and an agonist thereof in macrophage immune inflammation mediated diseases. The invention provides application of leucine aminopeptidase 3 or leucine aminopeptidase 3 agonist substances in preparation of drugs for prevention, treatment and / or adjuvant treatment of macrophage immune inflammation mediated diseases. According to the invention, it is found for the first time that the expression level of LAP3 in macrophages is increased under an acute stress condition, and the limiting effect of LAP3 on generation and development of sepsis and acute hepatitis is disclosed; the invention discloses that the knockout of the LAP3 can remodel a macrophage metabolic network, reduce oxidative phosphorylation, promote ROS (reactive oxygen species) production and activate TAK1, thereby promoting the activation of a downstream inflammation signal channel and finally promoting macrophage inflammation. A new target spot and a theoretical basis can be provided for clinical diagnosis and treatment of macrophage-mediated inflammation by illuminating the effect of LAP3 on regulating and controlling macrophage inflammation and a molecular mechanism of LAP3.

The invention discloses an application of Tapinarof in improvement of a tumor treatment effect. According to the application, a compound Tapinarof is found through screening, experimental research finds that the Tapinarof has an anti-tumor effect, and the Tapinarof can enhance the anti-tumor function of T cells, so that the curative effects of an immune checkpoint inhibitor and adoptive T cell therapy are improved, and the Tapinarof and the immune checkpoint inhibitor / adoptive cell transfer therapeutic agent have a synergistic effect in combined treatment of tumors. The discovery supports the potential value of the Tapinarof as an adjuvant therapy drug in clinical application of cancer immunotherapy.

The application provides a breast cancer patient lymph node metastasis prediction model without clinical pathological characteristics, comprising the following steps: after three-dimensional reconstruction of two-dimensional lung enhanced CT films, an axillary lymph node atlas is established, all axillary lymph nodes in the atlas are selected as ROI regions, and more than 5 combined image features of each axillary lymph node are selected to distinguish whether breast cancer has axillary lymph node metastasis; and a logistic regression machine learning prediction model is used to construct the breast cancer patient axillary lymph node metastasis prediction model. The model established by the application can non-invasively predict whether breast cancer has axillary lymph node metastasis, the clinical pathological characteristics of the patient are not included in the model, and the image cutting in the model is not based on breast tumors, but based on axillary lymph nodes; the model is used to determine a suitable axillary treatment scheme, thereby avoiding unnecessary axillary surgery and complications, and helping to carry out more accurate surgery and adjuvant therapy mode of breast cancer.

The invention provides diagnostic methods for identifying individuals having a lung cancer (e.g., NSCLC) suitable for treatment a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) after adjuvant therapy (e.g., after a platinum-based adjuvant therapy) and therapeutic methods for treating lung cancer (e.g., NSCLC) in an individual identified as one who may benefit from treatment with a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the individual following an adjuvant therapy (e.g., after a platinum-based adjuvant therapy). Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, assays thereof, kits thereof, and articles of manufacture thereof) for use in identifying patients suitable for treatment and for treating lung cancer (e.g., NSCLC) in an identified individual.

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the adjuvant treatment after tumour resection of patients with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).

The invention relates to the field of biological medicine, in particular to application of DDX39B protein or gene as a target spot in treatment and detection of head and neck squamous cell carcinoma, the DDX39B gene is highly expressed in HNSCC tissue, and the DDX39B protein can be used as a kit or a detection marker according to the discovery, namely, the content of the DDX39B protein in a patient can be detected, and the content of the DDX39B protein in the patient can be detected. The expression level can be used as a powerful prediction index independent of the traditional clinical staging, which is beneficial for clinicians to formulate a more targeted follow-up plan and a more positive adjuvant therapy strategy; besides, the DDX39B gene can also be used as a potential treatment target of the head and neck squamous cell carcinoma, expression of the DDX39B gene is reduced by constructing siRNA, the purposes of inhibiting migration and growth of cancer cells and reducing tumor cells are achieved through cell and animal experiments, and the discovery can be used for purposefully treating the head and neck squamous cell carcinoma.

The invention belongs to the technical field of biomedicine, and discloses an antibody for evaluating the curative effect of infantile pneumonia asthma and application of the antibody. The heavy chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 2-4, the light chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 6-8, the dissociation constant of the monoclonal antibody and an IL-5R antigen reaches 2.435 * 10 <-1 > / L, and the affinity is high. The antibody can accurately evaluate the curative effect of infantile pneumonia and asthma by detecting the lung function, the ratio of eosinophilic granulocytes in bronchoalveolar lavage fluid and lung tissue inflammation, can also significantly improve airway obstruction and inflammation of asthma model mice, has an effect superior to that of dexamethasone, solves the problems that existing curative effect evaluation is lack of specific tools and has large side effects of therapeutic drugs, and has good clinical application prospects. And a new scheme is provided for curative effect evaluation and adjuvant therapy of infantile pneumonia asthma.

The application provides a feline parvovirus antibody and application, a heavy chain variable region amino acid sequence of the feline parvovirus antibody 3E8 is shown as SEQ ID NO:1; a light chain variable region amino acid sequence is shown as SEQ ID NO:2.The monoclonal therapy group of the parvovirus antibody obtained in the application has a 60% higher cure rate than the adjuvant therapy group, further indicating that the feline parvovirus monoclonal antibody injection has a better treatment effect on the test cat infected with FPV.The monoclonal antibody has very high neutralization activity through in vitro cell level neutralization test and animal protection test, can specifically treat FPV, and is simple to prepare and convenient to operate, and has great significance for preventing and treating the disease.

According to the technical scheme, the pancreatic cancer prognosis prediction system based on deep learning is characterized by comprising a data input module, a preprocessing module, a feature extraction module, a cross sequence attention fusion module and a multi-task prediction module. The system disclosed by the invention can accurately predict the overall lifetime (OS) and the disease-free lifetime (DFS) of the patient by analyzing the preoperative multi-sequence magnetic resonance imaging (MRI) image of the patient, and carries out risk stratification. More importantly, clinical doctors can be guided to formulate personalized adjuvant therapy schemes for patients with different risk levels, for example, whether the patients can benefit from postoperative adjuvant chemotherapy or immunotherapy or not is judged, and therefore precise medical treatment is achieved, the treatment effect is improved, and invalid treatment is avoided.

The invention provides a marker, a kit containing the marker, application of the marker and a use method of the marker. The marker comprises at least one selected from the group consisting of MUC1, MUC5AC, and Claudin18.2. The invention also relates to a method for preparing the marker. The marker and the kit containing the marker can be used for predicting prognosis of the intrahepatic cholangiocarcinoma, predicting the curative effect of targeted therapy and postoperative adjuvant therapy on the intrahepatic cholangiocarcinoma based on tumor expression states, and performing classified prediction on a big bile duct type and a small bile duct type of the intrahepatic cholangiocarcinoma. The disclosure also provides a method of cancer prognosis comprising detecting the expression of the marker and predicting the degree of benefit from post-operative adjuvant therapy in a subject, and / or the prognosis of cancer, particularly intrahepatic cholangiocarcinoma, in a subject. The present disclosure provides universal markers that can be used to predict the efficacy of postoperative adjuvant therapy, such as postoperative adjuvant chemotherapy, on intrahepatic cholangiocarcinoma.

The present application belongs to the tumor precision medicine and artificial intelligence medical technology field, and particularly relates to a non-small cell lung cancer neoadjuvant immunotherapy efficacy prediction method based on transfer learning. The method first pretreats the non-small cell lung cancer immunotherapy cohort and the neoadjuvant immunotherapy cohort, selects immunotherapy and neoadjuvant immunotherapy characteristic genes, and based thereon, carries out deep learning training on the immunotherapy cohort to obtain a basic model, finally, the basic model is fine-tuned to the neoadjuvant immunotherapy training data set through transfer learning, and finally used to the neoadjuvant immunotherapy cohort to predict the neoadjuvant immunotherapy effect. The present application improves the stability and generalization ability of the model in the small sample neoadjuvant treatment scene through gene selection and transfer fine-tuning, and can be used for clinical auxiliary decision and population stratification.

The invention discloses a sensitizing drug for resisting breast cancer by radiotherapy and a screening method and application thereof, and belongs to the field of biomedicine.The method comprises the steps that an in-vitro radiotherapy resistance model is constructed, a clinical segmentation radiotherapy dose increasing mode is simulated, stable acquired radiotherapy resistance is induced to be generated, and a carrier is provided for drug screening; natural plant small molecule compounds are used for treatment, and through concentration and time gradient dual control, the reversion ability of the natural plant small molecule compounds to radiotherapy resistance phenotypes is investigated; a multi-dimensional joint detection system is established, multi-level comprehensive evaluation is performed from cell survival and the like, the limitation of a single index is broken through, and the screening accuracy and reliability are improved; dNA damage repair is dynamically monitored through immunofluorescence, comet electrophoresis and the like, and the drug action mechanism is revealed. The medicine screened by the method is suitable for primary and acquired radiotherapy resistance patients, can effectively improve the radiotherapy curative effect, provides a new medicine source and scheme for clinical problems, and opens up the application of the compound in preparation of radiosensitizers or adjuvant therapy medicines.

The invention relates to the technical field of biological medicine. The invention provides an application of bifidobacterium breve lw01 in preparation of a product for prevention or adjuvant therapy of obesity-related tumors, and also provides an application of the bifidobacterium breve lw01 in a product for regulating intestinal flora and bile acid metabolism level. In the invention, bile acid (such as taurocholic acid TCA) is used as an intervention target, and the bifidobacterium breve lw01 is used for targeted regulation of disordered bile acid metabolism in an obesity state, so that the promotion effect of obesity on tumor growth is remarkably relieved, and finally, the purpose of inhibiting the development of obesity-related tumors is achieved.

The present application belongs to the field of biopharmaceutical technology. More specifically, the present application relates to a humanized single-domain antibody that binds to serum albumin, as well as a multispecific antibody, fusion protein, and conjugate comprising the single-domain antibody. The humanized single-domain antibody of the present application is capable of efficiently binding to human serum albumin, thereby extending the in vivo half-life of the molecule to which it is attached. The humanized single-domain antibody of the present application, as well as the multispecific antibody, fusion protein, and conjugate comprising the single-domain antibody, can be used to prepare a medicament for the prevention and / or treatment or adjuvant treatment of tumors, infections, autoimmune diseases, metabolic-related diseases, or developmental-related diseases.

The application belongs to the field of biological medicine, and discloses application of an RNA helicase DHX33 inhibitor in preparation of a drug for treating or adjuvant treating thyroid cancer. The application establishes an important role of DHX33 protein in development of thyroid cancer, and provides an inhibitor having an action of inhibiting DHX33 helicase activity, thereby causing lipid peroxidation mediated by DHX33 deletion, and inducing interleukin 24 (IL-24) expression in thyroid cancer cells. The inhibitor can rapidly induce cancer cell ferroptosis, and significantly inhibit thyroid cancer cell proliferation through up-regulation of IL-24, and therefore has important medical development value.